Esperion Therapeutics Stock News

Esperion Therapeutics (ESPR) specializes in cholesterol lowering medications. President and CEO Sheldon Koenig joins Nicole Petallides to give an overview of the company.

Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock?

Innovation is expected to continue to drive growth of the Medical-Drugs industry. UTHR, ESPR, HRTX, LYRA and ALDX may prove to be good additions to one's portfolio.

Esperion Therapeutics reported strong Q4 and full-year revenue growth, with total revenue increasing 72% YoY to $32.3M in Q4 and 54% YoY to $116M for the full year. The company expects a true inflecti

Esperion's (ESPR) fourth-quarter earnings and sales beat estimates on the back of better-than-expected collaboration revenues.

Esperion Therapeutics (ESPR) came out with a quarterly loss of $0.50 per share versus the Zacks Consensus Estimate of a loss of $0.53. This compares to loss of $0.76 per share a year ago.

Esperion Therapeutics (ESPR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ANN ARBOR, Mich., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced it will report fourth quarter and full year 2023 financial results before the market opens on Tuesday, Febr

The stock market, as measured by the S&P 500 index SPX, has broken out strongly to the upside, trading at new intraday and closing highs. The breakout came on Jan. 19, over the 4,800 level.

Esperion Therapeutics' stock gapped down after news of a stock offering but fortunately never reached the $1.50 offering price. The presentation at the JP Morgan Healthcare Conference provided little

Esperion Therapeutics (NASDAQ: ESPR ) stock is falling on Friday after the pharmaceutical company announced details for a public offering of its shares. This public offering has Esperion Therapeutics

Esperion Therapeutics has a potential blockbuster drug that is gaining traction among the medical community. The company's main drugs, NEXLIZET and NEXLETOL, have been approved by the FDA and offer al

Daiichi Sankyo amends its existing collaboration with Esperion (ESPR), including the resolution of a commercial dispute over milestone payments. This amendment is valued at $125 million.

Esperion Therapeutics has reached a deal with Daiichi Sankyo to resolve a commercial dispute with an amendment to their ongoing collaboration.  Daiichi Sankyo Europe GmbH, the company's European arm

Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock?